News - Pangea Biomed

November 19, 2024

Pangea Biomed Named to Fast Company’s Fourth Annual List of the Next Big Things in Tech

Pangea Biomed, the startup behind the advanced cancer intelligence AI platform ENLIGHT, today announced that it has been named to Fast Company’s fourth annual Next Big Things in Tech list, honoring emerging technology that has a profound impact for industries.

October 24, 2024

Pangea Biomed Begins Pilot Collaboration with the OHSU Knight Cancer Institute to Improve Cancer Therapy Precision

Pangea Biomed, the startup behind the advanced cancer response prediction platform ENLIGHT, today announced the beginning of a pilot collaboration with the Knight Cancer Institute at Oregon Health and Science University (OHSU).

October 2, 2024

Dr. Kenneth Aldape from the U.S. National Cancer Institute Joins Pangea Biomed’s Scientific Advisory Board

Pangea Biomed, the startup behind the world’s most advanced cancer response predictor, ENLIGHT, announced that Dr. Kenneth D. Aldape, M.D., has joined the company’s scientific advisory board.

September 5, 2024

Pangea Biomed Joins Second Phase of LiquidBX Consortium to Improve Cancer Detection and Treatment Response Prediction

Pangea Biomed, the startup behind the advanced cancer response prediction platform ENLIGHT, today announced its participation in the next phase of the LiquidBX consortium.

August 7, 2024

Pangea Biomed Partners with Hadassah and Ultima Genomics for Solid Tumor Cancer Treatment Research at Sharett Cancer Institute

Pangea Biomed, the startup behind the world’s most advanced cancer response predictor, ENLIGHT, is announcing a strategic collaboration with the Sharett Institute of Oncology and Hadassah Cancer Research Institute (HCRI) at the Hadassah University Hospital Ein-Kerem and Ultima Genomics, the developer of a revolutionary architecture for high-throughput genomic sequencing.

July 4, 2024

Deep learning AI predicts response to cancer treatment

Artificial intelligence software developed by Pangea Biomed can predict the chances that a patient will respond to cancer treatment by looking at tumor histopathology images.

July 4, 2024

Pangea’s AI imaging platform predicts cancer treatment response

The company’s published study shows that its AI-powered Enlight-DP platform can predict cancer treatment response from histopathology slides.

July 3, 2024

Published Findings from Pangea Biomed Validate AI Method for Predicting Cancer Treatment Responses from Tumor Images

Pangea Biomed, the company behind the world’s most advanced cancer response predictor, ENLIGHT, today announced that new findings establishing the efficacy of its novel ENLIGHT-DP platform have been published in Nature Cancer. The study, conducted in collaboration with researchers from the Australian National University and from the US National Cancer Institute, reveals that combining ENLIGHT with the DeepPT approach for inferring gene expression from H&E slide scans significantly advanced the ability to predict therapeutic responses across multiple cancer types and drugs from histopathology images.

February 22, 2024

Using AI to Revolutionize Precision Oncology

Dr. Amar Drawid sat down with Tuvik Beker to discuss the evolution of precision medicine, the challenges in matching the right drugs to the right patient, and how Pangea uses AI to analyze expression data and gene interaction maps to select the most effective drugs for individual patients.

December 12, 2023

Startups Are Using AI to Predict Responses to Cancer Drugs

Brian Gormley talked with Tuvik Beker and other AI and oncology experts about how startups are using AI to accurately diagnose and treat cancer patients.